๐Ÿ‡ฎ๐Ÿ‡ชIreland
16ยฐC Partly Cloudy ยท Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› HCC - Hepatocellular Carcinoma
Clinical trial register · China

HCC - Hepatocellular Carcinoma Trials in China, 2026

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage โ€” all 19052 matching records held by the registry are in this view. Synced 22 Sep 2026, 11:10 UTC
19052
Studies in scope
all four open statuses
11786
Recruiting now
open to new participants
2009
Lead sponsors
across recruiting studies
Top sites
Shanghai 5 Tianjin 4 Wuhan 3 Nanjing 3 Beijing 2
Narrow the registerReset
Recruitment status
Phase
Site location
Shanghai5 Tianjin4 Wuhan3 Nanjing3 Beijing2
All 17 locations
Target enrolment
to

HCC - Hepatocellular Carcinoma trials in China

26 of 19052 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Chinese sites
Start
Not yet open
Shuganhuazhuo Formula for Advanced Hepatocellular Carcinoma With Damp-Heat Syndrome
NCT07691645HCC - Hepatocellular Carcinoma, Chinese Herbal Medicine, ICG (Indocyanine Green), Overall Survival (All-cause Mortality)
Xiang-Qian
Phase 2
120
Hangzhou
2027-09-01
Recruiting
Iparomlimab and Tuvonralimab With Lenvatinib, Radiotherapy, and HAIC for Hepatocellular Carcinoma With Portal Vein Tumor Thrombus
NCT07776080HCC - Hepatocellular Carcinoma
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Phase 2
35
Wuhan
2026-10-01
Not yet open
Epalrestat Combined With HAIC, Donafenib and Tislelizumab as First-line Treatment for Patients With Unresectable HCC and Diabetes
NCT07557914HCC - Hepatocellular Carcinoma, Diabetes
Haibo Shao
Phase 2
32
Shenyang
2026-10
Not yet open
Evaluate the Safety and Efficacy of Combination Therapy With SYS6090 Injection for Hepatocellular Carcinoma
NCT07761286HCC - Hepatocellular Carcinoma
CSPC Megalith Biopharmaceutical Co.,Ltd.
Phase 1/2
288
Harbin
2026-09-30
Recruiting
Iparomlimab/Tuvonralimab Plus SBRT and Lenvatinib for Perioperative Treatment of Potentially Resectable Intermediate-Stage HCC
NCT07801287HCC - Hepatocellular Carcinoma
Tianjin Medical University Cancer Institute and Hospital
Phase 2
20
Tianjin
2026-09-01
Recruiting
Effect of Laparoscopic Hepatectomy Combined With Splenectomy on Hepatic Functional Reserve and Immune Function
NCT07811687Liver Cirrhosis, HCC - Hepatocellular Carcinoma, Hypersplenism
Northern Jiangsu People's Hospital
Observational
30
Yangzhou
2026-08-02
Active, closed
Eparlitozoviril as Adjuvant Therapy for Resectable HCC With MVI
NCT07658105HCC - Hepatocellular Carcinoma
Tianjin Medical University Cancer Institute and Hospital
Phase 2
60
Tianjin
2026-06-12
Recruiting
A Study of Neoadjuvant Tislelizumab Plus Lenvatinib in Resectable HCC at High Risk of Recurrence
NCT07475026HCC - Hepatocellular Carcinoma
Tianjin Medical University Cancer Institute and Hospital
Phase 3
198
Tianjin
2026-06-09
Recruiting
Ipilimumab N01 Combined With Sintilimab, Bevacizumab Biosimilar, and Hepatic Arterial Infusion Chemotherapy as Conversion Therapy for Unresectable Intermediate-Advanced Hepatocellular Carcinoma
NCT07560488HCC - Hepatocellular Carcinoma, Conversion Therapy
Tianjin Medical University Cancer Institute and Hospital
Phase 2
43
Tianjin
2026-03-30
Recruiting
Intelligence System for Predicting Atezolizumab-Bevacizumab Response and Clinical Outcomes in Unresectable Hepatocellular Carcinoma
NCT07495735HCC - Hepatocellular Carcinoma, Atezolizumab and Bevacizumab in Hepatocellular Carcinoma
First Affiliated Hospital of Wenzhou Medical University
Observational
400
Wenzhou
2026-03-22
Recruiting
A Multicenter Prospective Study on the Performance of Spectral CT for Evaluating Treatment Response After TACE in Hepatocellular Carcinoma
NCT07351669HCC - Hepatocellular Carcinoma, TACE(Transcatheter Arterial Chemoembolization), CT
Zhongda Hospital
Observational
121
Nanjing
2026-01-20
Recruiting
Phase IIb Study of AST-3424 in Patients With AKR1C3-high Expressing Advanced Hepatocellular Carcinoma
NCT07310173HCC - Hepatocellular Carcinoma
Zhejiang Hisun Pharmaceutical Co. Ltd.
Phase 2
75
Nanjing
2026-01-01
Recruiting
The Efficacy of Sequential Treatment With Bevacizumab Combined With Atezolizumab in Advanced Liver Cancer With MASLD
NCT07285850HCC - Hepatocellular Carcinoma
Eastern Hepatobiliary Surgery Hospital
Phase 2/3
20
Shanghai
2025-10-20
Recruiting
A Study of GV20-0251 in Advanced or Refractory Solid Tumors
NCT07106827HCC - Hepatocellular Carcinoma, Cholangiocarcinoma, Melanoma, NSCLC (Non-small Cell Lung Cancer)
West China Hospital
Phase 1
10
Chengdu
2025-09-04
Recruiting
A Phase 1 Study of TGI-5 as Monotherapy and in Combination With Nivolumab in Subjects With Locally Advanced/Metastatic Solid Tumors
NCT07376707CRC (Colorectal Cancer), Melanoma (Skin Cancer), HCC - Hepatocellular Carcinoma, NSCLC (Non-small Cell Lung Cancer)
Hefei TG ImmunoPharma Co., Ltd.
Phase 1
194
Shanghai
2025-06-12
Recruiting
FGF19 Overexpression Combination Unified Study in HCC-19
NCT06978933HCC - Hepatocellular Carcinoma
RenJi Hospital
Phase 2
42
Shanghai
2025-04-30
Recruiting
ICIs and Anti-VEGF Antibody/TKIs With or Without Interventional Therapy for Advanced HCC
NCT07157969HCC - Hepatocellular Carcinoma
Peking Union Medical College Hospital
Phase 2
300
Beijing
2025-02-19
Not yet open
QL1706 As Second-line Treatment in Patients with Advanced Hepatocellular Carcinoma
NCT06822985HCC - Hepatocellular Carcinoma
Wan-Guang Zhang
Phase 1
21
Wuhan
2025-02-01
Recruiting
The Impact of Emotional Stress on Immunotherapy Outcomes in Liver Cancer Patients: A Multi-Cohort Study
NCT07141056HCC - Hepatocellular Carcinoma, Psychological Distress, Immune Checkpoint Inhibitors (ICIs), Cancer, Treatment-Related
Guilin Medical University, China
Observational
700
Zhanjiang, Guilin, Shaoyang
2025-01-01
Recruiting
Mts105 for Advanced Hepatocellular Carcinoma
NCT06689540Liver Cancer, Adult, Metastatic Liver Cancers, HCC - Hepatocellular Carcinoma, Hepatocellular Carcinoma (HCC)
Shen Lin
Phase 1
14
Beijing
2024-11-18
Active, closed
Sequential TACE-SBRT Combined With Targeted Immunotherapy for Patients With Intermediate to Advanced Liver Cancer
NCT07230080HCC - Hepatocellular Carcinoma, SBRT, TACE, Immunotherapy
Nanfang Hospital, Southern Medical University
Observational
17
Guangzhou
2024-09-01
Recruiting
Efficacy and Safety of Radiotherapy in Oligoprogressive HCC Following First-line PD-1 Therapy
NCT06870942HCC - Hepatocellular Carcinoma, Radiotherapy
Shanghai Zhongshan Hospital
Phase 2
35
Shanghai
2022-07-28
Recruiting
Efficacy and Safety of SIRT-Y90 in Combination With Atezo + Bev for Unresectable Hepatocellular Carcinoma
NCT07610551HCC - Hepatocellular Carcinoma
Air Force Military Medical University, China
Observational
50
Xiโ€™an
2022-02-09
Active, closed
Prospective Evaluation of a Locked Risk-Stratified Surveillance Strategy for Extrahepatic Metastasis in Hepatocellular Carcinoma
NCT07444905HCC - Hepatocellular Carcinoma, Machine Learning, Evaluation
Tongji Hospital
Observational
1,523
Wuhan
2022-02-01
Rows per page Showing 1–26 of 26
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 25 September 2026. https://priyalifescience.com/clinical-trials-china/condition/hcc-hepatocellular-carcinoma

Query this register directly
GET /api/trials?country=cn&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in China and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 19,052 studies in total at the last sync on 22 Sep 2026, 11:10 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 26 of those studies listing the condition HCC - Hepatocellular Carcinoma.

How many HCC - Hepatocellular Carcinoma trials are recruiting in China?

18 of the 26 studies on this page are recruiting new participants as of the 22 Sep 2026, 11:10 UTC sync. A further 5 have not yet opened recruitment, 3 are active but closed to new participants, and 0 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (HCC - Hepatocellular Carcinoma), 26 studies
PhaseStudiesRecruitingShare
Phase 211842.3%
Observational7526.9%
Phase 14315.4%
Phase 1/2207.7%
Phase 2/3113.8%
Phase 3113.8%

Most active sponsors

Lead sponsors with the most studies (HCC - Hepatocellular Carcinoma)
Lead sponsorStudiesRecruiting
Tianjin Medical University Cancer Institute and Hospital43
Zhongda Hospital21
Air Force Military Medical University, China11
CSPC Megalith Biopharmaceutical Co.,Ltd.10
Eastern Hepatobiliary Surgery Hospital11
First Affiliated Hospital of Wenzhou Medical University11
Guilin Medical University, China11
Haibo Shao10
Hefei TG ImmunoPharma Co., Ltd.11
Nanfang Hospital, Southern Medical University10
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.